Investigational drug · Phase 2
BHV-2100
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Migraine.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "BHV-2100"
First trial start
2024
Oct 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BHV-2100", any sponsor or status.
Conditions studied
As listed on its trial records.
- Migraine
Approved drugs for the same conditions: Migraine · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "BHV-2100" as an intervention, largest first.
- Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of MigrainePivotal-lookingCompleted
Biohaven Therapeutics Ltd.Industry
NCT06603623 · 647 participants · Start Oct 10, 2024 · Primary completion Mar 24, 2025
Drug: BHV-2100; BHV-2100 and 1 more · For: Migraine
Sites: Gilbert, Arizona; Encino, California; Los Alamitos, California · 60 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Migraine
- AXS-07meloxicam-rizatriptanPhase 31 trial
Axsome Therapeutics, Inc. · Migraine
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- MEDI0618Phase 21 trial
AbbVie · Migraine
- MTX101Phase 21 trial
Manistee Therapeutics · Migraine
- PRT-064040Phase 21 trial
Sichuan Purity Pharmaceutical Technology Co., Ltd. · Migraine
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.